About BiDil (isosorbide dinitrate/hydralazine HCl) for Heart Failure

Heart failure steals precious moments away.

BiDil is the first heart failure (HF) treatment specifically for African Americans

BiDil has been approved by the US Food and Drug Administration (FDA) for use by self-identified African American patients in addition to routine HF medicines.

In a large clinical study called the African American Heart Failure Trial (A-HeFT), a group of African American patients with HF took BiDil along with their usual HF medicines. A similar group of patients took only their usual medicines. The study found that BiDil users had a 43% better survival rate during the course of the study and were 39% less likely to need hospitalization for HF. The BiDil group also reported a significant improvement in their day-to-day functioning. Results from the trial were so compelling that the trial was stopped early due to the significant survival benefit seen with BiDil. The FDA based the approval of BiDil primarily on the results from A-HeFT.¹

A-HeFT was the first clinical trial to specifically study African American men and women with HF. Most patients in the clinical study of BiDil received routine HF medicines.¹

Once you know about BiDil, you can talk with your doctor to see if BiDil may be right for you.

Please click here to see full Prescribing Information for BiDil.